

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
02 January 2025 (02.01.2025)



(10) International Publication Number
WO 2025/007000 A1

(51) International Patent Classification:

C07D 498/04 (2006.01) A61P 35/00 (2006.01)
C07D 498/16 (2006.01) A61K 31/553 (2006.01)

(21) International Application Number:

PCT/US2024/036174

(22) International Filing Date:

28 June 2024 (28.06.2024)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/511,279	30 June 2023 (30.06.2023)	US
63/513,796	14 July 2023 (14.07.2023)	US
63/582,484	13 September 2023 (13.09.2023)	US
63/600,560	17 November 2023 (17.11.2023)	US
63/646,597	13 May 2024 (13.05.2024)	US

(71) Applicant: **KUMQUAT BIOSCIENCES INC.** [US/US];
10770 Wateridge Circle, Suite 120, San Diego, California
92121 (US).

(72) Inventors: **WU, Baogen**; 10770 Wateridge Circle, Suite
120, San Diego, California 92121 (US). **REN, Pingda**;
10770 Wateridge Circle, Suite 120, San Diego, California
92121 (US). **LI, Liansheng**; 10770 Wateridge Circle, Suite
120, San Diego, California 92121 (US).

(74) Agent: **MALECHA, James** et al.; Wilson Sonsini
Goodrich & Rosati, 650 Page Mill Road, Palo Alto, Cali-
fornia 94304 (US).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM,
DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,
HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG,
KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY,
MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA,
NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO,
RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH,
TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS,
ZA, ZM, ZW.

(54) Title: SUBSTITUTED CONDENSED TRICYCLIC AMINE COMPOUNDS AND USES THEREOF AS RAS INHIBITORS




FIG. 1

	1	20	40
K-Ras	mte-----	gagvgksal	tiqliqnhfv deydptieds yrkqvvidge 49
(SEQ ID No. 9)	mte-----	gagvgksal	tiqliqnhfv deydptieds yrkqvvidge 49
H-Ras	mte-----	gagvgksal	tiqliqnhfv deydptieds yrkqvvidge 49
(SEQ ID No. 10)	mte-----	gagvgksal	tiqliqnhfv deydptieds yrkqvvidge 49
N-Ras	mte-----	gagvgksal	tiqliqnhfv deydptieds yrkqvvidge 49
(SEQ ID No. 11)	maankpkqgn slalhkvimv	gagvgksal	tlqfmydefv edyepthkads yrkkvvlidge 60
Ra1A	maankpkqgn slalhkvimv	gagvgksal	tlqfmydefv edyepthkads yrkkvvlidge 60
(SEQ ID No. 12)	maankskqgs slalhkvimv	gagvgksal	tlqfmydefv edyepthkads yrkkvvlidge 60
Ra1B	maankskqgs slalhkvimv	gagvgksal	tlqfmydefv edyepthkads yrkkvvlidge 60
(SEQ ID No. 13)			
	60	80	100
K-Ras	tcldildta gqdeysamrd qymrtgegfl cvfainntks fedihlyreq ilkrvkdsed- 108		
H-Ras	tcldildta gqdeysamrd qymrtgegfl cvfainntks fedihlyreq ilkrvkdsdd- 108		
N-Ras	tcldildta gqdeysamrd qymrtgegfl cvfainntks fedihlyreq ilkrvkdsdd- 108		
Ra1A	cvqidildta gqcdyaaaird nyfrsgcgfl cvfsitcmcs feataefreq ilrvk-cdcn 119		
Ra1B	evqidildta gqcdyaaaird nyfrsgcgfl lvfsitehes ftataefreq ilrvkaeedk 120		

(57) Abstract: The present disclosure provides compounds of formula (Vc) and pharmaceutically acceptable salts thereof, and methods of using the same. The compounds and methods have a range of utilities as therapeutics, diagnostics, and research tools. In particular, the subject compositions and methods are useful for reducing signaling output of oncogenic protein.

[Continued on next page]

(84) Designated States (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*
- *as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))*

Published:

- *with international search report (Art. 21(3))*
- *with sequence listing part of description (Rule 5.2(a))*